Markets Featured

American Drug Prices Just Broke a 63-Year Record

Prescription drug prices are falling at the fastest annual rate since 1963 — seven straight months of deflation in a category that almost never deflates. Washington is fighting over the credit. The real question is who absorbs the cut.

Alpha One

19 Aug 2026 • 7 min read

For sixty-three years, one rule held in American healthcare: prescription drug prices go up. Through recessions, price-control fights, patent cliffs, and every reform Congress ever passed, the Consumer Price Index category tracking what Americans pay at the pharmacy counter rose almost without interruption.

That rule just broke.

The July CPI data show prescription drug prices down 0.8% for the month and down 3.1% from a year earlier — the steepest annual decline since 1963. It is the seventh consecutive monthly drop, the longest uninterrupted stretch of falling drug prices in the roughly 80-year history of the index. In an economy still digesting tariff pass-through and an oil shock, the single most reliably inflationary category in the American household budget is deflating.

Washington immediately went to war over the credit. The White House says its Most Favored Nation pricing deals did it. Health economists point instead to Medicare price negotiation — a Biden-era law the current administration inherited and kept. Both sides are partially right, and both are arguing about the wrong thing. The question that matters for investors is not who gets credit for the decline. It is whether the decline is a blip or the beginning of a structural repricing of the world's most profitable drug market — and who absorbs the cut if it is.

What is actually in the number

The CPI prescription drug index measures transaction prices at the retail pharmacy counter — what consumers and their insurers actually pay, weighted toward the generics that fill roughly nine of every ten American prescriptions. That construction matters, because it tells you which of the competing explanations carry real weight.

Three engines are pulling the index down at once.

Medicare negotiation went live. On January 1, the first ten drug prices ever negotiated by Medicare took effect — discounts of 38% to 79% against 2023 list prices, on drugs that accounted for $56.2 billion in gross Part D costs in 2023, roughly a fifth of the program. About nine million Medicare enrollees take these ten drugs. The federal government estimates roughly $6 billion in annual program savings and $1.5 billion less in out-of-pocket costs. Those lower transaction prices flow directly into the index. And the program compounds: agreements for the next fifteen drugs are already signed, with prices effective January 1, 2027.

The GLP-1 price war reached the cash register. Under the November agreements with the administration, Eli Lilly and Novo Nordisk cut cash prices for Ozempic, Wegovy, Mounjaro, and Zepbound to roughly $350 a month through the new direct-purchase channel, on a path toward $245 — against list prices that stood above $1,000 as recently as last year. Medicare now pays $245 with a $50 beneficiary copay, and covers obesity drugs for the first time through a pilot that began this summer. The most expensive fast-growing category in American pharmacy is getting cheaper at the point of sale — exactly where CPI measures.

Generic deflation never stopped. Beneath the branded headlines, the generic market — the bulk of the index by prescription volume — remains brutally competitive, and biosimilar competition against branded biologics is eroding prices faster with each launch cycle. Boehringer Ingelheim cut the list price of Jardiance, one of America's most prescribed diabetes drugs, by 40% this year.

Note what is largely missing from that list: the Most Favored Nation deals themselves. The 17 agreements announced since September — now covering companies representing an estimated 86% of the branded US market — commit manufacturers to offer their lowest developed-world prices to Medicaid and to cash buyers through the government's direct-purchase portal, and to price new launches at parity. What they mostly do not do is cut existing list prices in the commercial market. On January 1, the same month the portal launched, more than 350 branded medications took list-price increases — including roughly 80 from Pfizer, the first company to sign. One Harvard-affiliated researcher described the deals as nibbling "around the margins" of what drives high prices. The deflation is real; the marquee policy is, so far, the smallest part of it.

Briefings like this land in members' inboxes before the market prices them in. Join free →

Why this is structural, not a blip

A cynic can point at the list-price increases and call the whole thing theater. That misses the architecture being assembled underneath.

For four decades, the global pharmaceutical business model rested on a single load-bearing assumption: the United States pays. American net prices ran two to four times those in other rich countries, and that premium — not European or Japanese revenue — funded the industry's margins and its R&D budgets. Every mechanism now in motion attacks that premium from a different side:

Medicare negotiation is a ratchet. Ten drugs in 2026, fifteen more in 2027, and the eligible pool expands every year. Once a drug's negotiated price exists, it becomes the reference point for every other payer negotiation, formally or not.
MFN pricing inverts the arbitrage. Whatever their current enforcement gaps, the deals establish the principle — in signed agreements covering most of the branded market — that Americans should pay what Europeans pay. Companies retain an incentive to raise ex-US prices rather than cut US ones, but foreign governments are monopsony buyers with no intention of paying more. The gap closes mostly from the top.
The patent cliff does the rest. Between 2025 and 2030, the US market alone is projected to lose more than $230 billion in branded revenue to patent expirations, with Eliquis — one of the largest drug franchises in history — beginning to lose protection this year. Analysts increasingly expect biosimilar erosion to run faster than past cycles. Revenue rolling off patent gets repriced down 80-90%; in a deflating policy environment, its replacements launch into tougher pricing than the drugs they succeed.

Seven months of CPI deflation is what it looks like when those forces stop being forecasts and start being transactions.

Who absorbs the cut

Falling prices are not free. Someone's revenue line is on the other side of every one of those transactions, and the market is still sorting out whose.

The manufacturers with legacy-heavy portfolios carry the most exposure. A company whose earnings rest on ten-year-old franchises faces negotiated prices, biosimilars, and MFN reference pricing simultaneously. That is why the industry is in the middle of an acquisition sprint — Big Pharma entered the year racing to buy biotech assets against a $170 billion revenue hole, and pipeline depth has replaced dividend history as the thing worth paying for.

The middlemen face a different problem: shrinking gross-to-net spread. Pharmacy benefit managers monetize the gap between list and net prices. Every mechanism above — negotiated prices, cash-pay channels, direct-from-manufacturer portals — is a route around that gap. The fastest-growing pharmacy channels in America right now are the ones designed to bypass the rebate system entirely.

The winners are on the volume side. Cash-pay and direct-to-consumer channels gain share as branded cash prices fall toward defensible levels. Biosimilar manufacturers get the largest branded-revenue handoff in industry history. And insurers and self-funded employers — the entities that actually wrote the checks for the old premium — quietly book the savings.

There is also a macro reader on this trade: the Federal Reserve. Medical care was one of the stickiest components of services inflation through the entire post-pandemic cycle. A durably deflating drug index, in a week when the FOMC minutes dominate the calendar, removes one of the structural arguments that services inflation cannot come down. Small weight in the index; large weight in the argument.

What would change the story

Honesty requires the caveats. The MFN agreements are voluntary, largely unenforceable, and could be abandoned by either side. List prices on specialty drugs are still rising, and the gross-to-net gap remains opaque enough to hide a great deal. A single blockbuster launch priced aggressively — or a policy reversal after the next election — could flip the index positive again. And the CPI measures the retail counter, not the hospital pharmacy, where some of the steepest price increases this year (one Pfizer hospital product rose 400%) never touch the index at all.

But the burden of proof has shifted. For sixty years, the base case was that American drug prices rise and the rest of the world free-rides on the premium. Seven consecutive months of deflation, a negotiation program that compounds annually, signed MFN agreements covering most of the branded market, and the largest patent cliff in industry history all point the same direction. The era of the US as pharma's price-insensitive buyer of last resort is ending — not with a single law, but with every mechanism at once.

The political fight over credit will run through November. The repricing will run through the decade.

If this analysis was useful, this is what AlphaBriefing does every day — geopolitics and markets, connected to what it means for your money. Free members get the daily brief in their inbox; paid members get the investment frameworks, scenario pricing, and catalyst calendars behind the paywall.

Sign up free → — upgrade whenever it earns it.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.